About Zinc finger protein 692
Zinc finger protein 692 (ZNF692) is a protein
from Homo sapiens identified by UniProt accession
Q9BU19, 519 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Zinc finger protein 692 |
| UniProt accession | Q9BU19 |
| Gene | ZNF692 |
| Organism | Homo sapiens |
| Length | 519 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (45)
Diseases linked to this target (Open Targets).
- monocyte count · score 0.26
- systolic blood pressure · score 0.23
- erythrocyte count · score 0.17
- platelet count · score 0.14
- pathological myopia · score 0.14
- Myopia · score 0.11
- mean corpuscular volume · score 0.09
- neoplasm · score 0.09
- monocyte percentage of leukocytes · score 0.09
- platelet crit · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BU19-F1 | alphafold | PREDICTED | 53.36 | — |
Amino-acid sequence (519 residues)
MASSPAVDVS CRRREKRRQL DARRSKCRIR LGGHMEQWCL LKERLGFSLH SQLAKFLLDR YTSSGCVLCA GPEPLPPKGL QYLVLLSHAH SRECSLVPGL RGPGGQDGGL VWECSAGHTF SWGPSLSPTP SEAPKPASLP HTTRRSWCSE ATSGQELADL ESEHDERTQE ARLPRRVGPP PETFPPPGEE EGEEEEDNDE DEEEMLSDAS LWTYSSSPDD SEPDAPRLLP SPVTCTPKEG ETPPAPAALS SPLAVPALSA SSLSSRAPPP AEVRVQPQLS RTPQAAQQTE ALASTGSQAQ SAPTPAWDED TAQIGPKRIR KAAKRELMPC DFPGCGRIFS NRQYLNHHKK YQHIHQKSFS CPEPACGKSF NFKKHLKEHM KLHSDTRDYI CEFCARSFRT SSNLVIHRRI HTGEKPLQCE ICGFTCRQKA SLNWHQRKHA ETVAALRFPC EFCGKRFEKP DSVAAHRSKS HPALLLAPQE SPSGPLEPCP SISAPGPLGS SEGSRPSASP QAPTLLPQQ
Explore Zinc finger protein 692 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets